MX2023006856A - Composiciones de polvo seco con estearato de magnesio. - Google Patents

Composiciones de polvo seco con estearato de magnesio.

Info

Publication number
MX2023006856A
MX2023006856A MX2023006856A MX2023006856A MX2023006856A MX 2023006856 A MX2023006856 A MX 2023006856A MX 2023006856 A MX2023006856 A MX 2023006856A MX 2023006856 A MX2023006856 A MX 2023006856A MX 2023006856 A MX2023006856 A MX 2023006856A
Authority
MX
Mexico
Prior art keywords
dry powder
magnesium stearate
powder compositions
âμm
powder composition
Prior art date
Application number
MX2023006856A
Other languages
English (en)
Inventor
Kambiz Yadidi
Original Assignee
Otitopic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otitopic Inc filed Critical Otitopic Inc
Publication of MX2023006856A publication Critical patent/MX2023006856A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0023—Mouthpieces therefor retractable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición de polvo seco estable para inhalación incluye ácido acetilsalicílico en partículas que tienen un diámetro aerodinámico medio de masa (MMAD) en un intervalo de aproximadamente 1 µm a aproximadamente 5 µm. La composición de polvo seco puede contener un excipiente farmacéuticamente aceptable, tal como un estearato, en una cantidad que varía de aproximadamente 0.04% (p/p) a aproximadamente 0.06% (p/p), o de aproximadamente 0.4% (p/p) a aproximadamente 0.6% (p/p) de la composición.
MX2023006856A 2017-09-22 2020-03-12 Composiciones de polvo seco con estearato de magnesio. MX2023006856A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762562295P 2017-09-22 2017-09-22

Publications (1)

Publication Number Publication Date
MX2023006856A true MX2023006856A (es) 2023-06-22

Family

ID=65200304

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002769A MX2020002769A (es) 2017-09-22 2017-09-26 Composiciones de polvo seco con estearato de magnesio.
MX2023006856A MX2023006856A (es) 2017-09-22 2020-03-12 Composiciones de polvo seco con estearato de magnesio.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002769A MX2020002769A (es) 2017-09-22 2017-09-26 Composiciones de polvo seco con estearato de magnesio.

Country Status (9)

Country Link
US (3) US10195147B1 (es)
EP (1) EP3684338A4 (es)
JP (2) JP7493449B2 (es)
KR (2) KR102507987B1 (es)
CN (2) CN111315363B (es)
AU (1) AU2017432640B2 (es)
CA (1) CA3076353A1 (es)
MX (2) MX2020002769A (es)
WO (1) WO2019059953A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3607941A1 (en) * 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
WO2017109037A1 (en) * 2015-12-22 2017-06-29 Ventaleon Gmbh Treatment of moderate to severe influenza
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
WO2018222583A1 (en) 2017-05-30 2018-12-06 Rho Pharmaceuticals, Llc In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)
EP3684338A4 (en) * 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
NL2021637B1 (en) * 2018-09-14 2020-05-07 Stichting Katholieke Univ Breath sampler
WO2023205388A1 (en) * 2022-04-22 2023-10-26 Board Of Regents, The University Of Texas System Inhaled antibacterial formulations for treating lung infections

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
FR2580634B1 (fr) 1985-04-19 1988-08-05 Rhone Poulenc Sante Nouveau derive de l'acide acetylsalicylique, sa preparation et les compositions pharmaceutiques qui le contiennent
DE3814856A1 (de) 1988-05-02 1989-11-16 Verla Pharm Mittel zur prophylaxe des herzinfarkts und zur verhuetung des reinfarkts
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US20070117863A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5533502A (en) 1993-05-28 1996-07-09 Vortran Medical Technology, Inc. Powder inhaler with aerosolization occurring within each individual powder receptacle
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
JP2002529393A (ja) 1998-11-12 2002-09-10 フランク ジー． ピルキーウィッツ， 吸入システム
US20030176421A1 (en) 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
ATE392885T1 (de) 2000-02-28 2008-05-15 Pharmakodex Ltd Verabreichungssystemen für oral anzuwendende arzneimittel
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
EP1177805A1 (en) 2000-07-31 2002-02-06 Maryland Financial Inc. Powder inhaler
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
RU2003122515A (ru) 2000-12-22 2005-01-27 Эспен Аэроджелз, Инк. (Us) Порошок аэрогеля, включающий терапевтические средства
DE60101451T2 (de) 2001-03-05 2004-10-21 Pera Ivo E Inhaliergerät zur Verteilung von in einer Kapsel enthaltenen Medikamenten in Pulverform durch die Atemwege
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
GB0129270D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
US20040105821A1 (en) 2002-09-30 2004-06-03 Howard Bernstein Sustained release pharmaceutical formulation for inhalation
GB0226105D0 (en) 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
JP2006522834A (ja) 2003-04-09 2006-10-05 ワイス ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法
JP4943838B2 (ja) 2003-04-09 2012-05-30 ネクター セラピューティクス 空気入口シールドを備えたエアゾール化装置
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
US7041286B2 (en) 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
WO2005019151A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Ppar modulators
CN1838958A (zh) 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
WO2005039489A2 (en) 2003-09-24 2005-05-06 Polymerix Corporation Compositions and methods for the inhibition of bone growth and resorption
JP2011168615A (ja) * 2003-10-16 2011-09-01 Daiichi Sankyo Healthcare Co Ltd サリチル酸類含有経口組成物
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
WO2005041886A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Methods for generating or increasing revenues related to pain inhibitor commerce
US20070232575A1 (en) 2004-02-05 2007-10-04 Baulieu Etienne E Treatment of Pulmonary Artery Hypertension with Dhea, Dheas, Dhea Analogs, or Dhea Derivatives
EP1722767A2 (en) 2004-02-23 2006-11-22 Prolexys Pharmaceuticals, Inc. NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
CA2565813C (en) 2004-05-04 2010-10-26 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
US7189750B2 (en) 2004-05-05 2007-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
WO2006017354A1 (en) 2004-07-13 2006-02-16 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain
MX2007001561A (es) 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
WO2006060117A2 (en) 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007014391A2 (en) 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
CA2618974C (en) 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
JP2009519975A (ja) 2005-12-16 2009-05-21 ユニバーシティ・オブ・カンザス 治療薬を送達するナノクラスター
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
CN104758253A (zh) 2006-01-24 2015-07-08 安迅生物制药公司 大分子微球的制备技术
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
DK2068889T3 (da) 2006-08-10 2020-02-03 Roy C Levitt Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
GB0621957D0 (en) 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
GB0700839D0 (en) 2007-01-17 2007-02-21 Braithwaite Philip Device
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2008156709A1 (en) 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
CN101848733A (zh) 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
CA2692892A1 (en) 2007-07-24 2009-01-29 Michael Malakhov Technology for the preparation of microparticles
WO2009019598A2 (en) 2007-08-03 2009-02-12 Dr. Reddy's Laboratories Ltd. Inhalation therapy for respiratory disorders
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
US9358242B2 (en) 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US20110142914A1 (en) 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
WO2009086470A2 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
DE102008004386A1 (de) 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
JP2011510017A (ja) 2008-01-15 2011-03-31 ユニベルシテ・ドウ・ストラスブール 治療薬として有用なレゾルシン酸ラクトンの合成
BRPI0907196B1 (pt) 2008-02-21 2021-05-25 Kirin-Amgen Inc Uso de um antagonista de il-17ra-il-17rb
CN101951896B (zh) 2008-02-22 2012-11-28 韩兀生物制药株式会社 复合制剂
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
EP2274302A2 (en) 2008-04-04 2011-01-19 Irm Llc Compounds and compositions as itpkb inhibitors
WO2009128933A1 (en) 2008-04-15 2009-10-22 Sarcode Corporation Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
MX2010012457A (es) 2008-05-13 2010-12-07 Irm Llc Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa.
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
KR20110045004A (ko) 2008-07-15 2011-05-03 쉐링 코포레이션 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
MX2011000405A (es) 2008-07-18 2011-03-04 Prosonix Ltd Proceso para mejorar la cristalinidad.
WO2010011329A2 (en) 2008-07-23 2010-01-28 Map Pharmaceuticals, Inc. The delivery of powdered drug via inhalation
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BRPI0918253A2 (pt) 2008-09-12 2015-12-15 Critical Pharmaceuticals Ltd aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele
CA2755543A1 (en) 2009-03-13 2010-09-16 Nucitec S.A. De C.V. Compositions and methods for treatment and prevention of cardiovascular disease
WO2010117951A1 (en) 2009-04-06 2010-10-14 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
EP2421867B1 (en) 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Piperidine inhibitors of janus kinase 3
EP2429495A4 (en) 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
US9125999B2 (en) 2009-05-18 2015-09-08 Adamis Pharmaceuticals Corporation Dry powder inhaler dose counters
JP5720009B2 (ja) 2009-05-18 2015-05-20 アダミス ファーマシューティカルズ コーポレーション ドライパウダー吸入器
EP2437741A1 (en) 2009-06-01 2012-04-11 Biocopea Limited The use of amlexanox in the therapy of neutrophil-driven diseases
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
AU2011237679B2 (en) 2010-04-07 2014-11-06 Abbvie Inc. TNF-alpha binding proteins
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012041717A1 (en) * 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
JP6050758B2 (ja) 2010-12-07 2016-12-21 レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 乾燥粉末吸入器及びその作動方法
CN102058886A (zh) 2010-12-20 2011-05-18 云南白药集团无锡药业有限公司 医用粉雾剂及其应用
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
EP2696888B1 (en) 2011-04-12 2018-12-05 Moerae Matrix, Inc., Compositions and methods for preventing or treating pulmonary fibrosis
US20120306613A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Sensor allocation
KR102058256B1 (ko) 2011-06-17 2020-01-22 버그 엘엘씨 흡입성 약제학적 조성물들
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG11201400325WA (en) 2011-09-06 2014-03-28 Verona Pharma Plc Treating cough and tussive attacks
DK2790758T3 (da) 2011-12-16 2017-11-20 Indosys Ltd Kassette til en lægemiddeldosis og tilførselsindretning
US20130196906A1 (en) 2012-01-31 2013-08-01 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
NZ722952A (en) * 2012-02-28 2018-12-21 Iceutica Holdings Inc Inhalable pharmaceutical compositions
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
EP2831072B1 (en) 2012-03-26 2017-04-19 Arroyo BioSciences L.L.C. Novel sphingosine 1-phosphate receptor antagonists
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
KR102373259B1 (ko) 2012-05-03 2022-03-17 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
SG11201407676VA (en) 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
WO2013188979A1 (en) 2012-06-20 2013-12-27 Frank Gu Mucoadhesive nanoparticle delivery system
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US20150224129A1 (en) 2012-10-03 2015-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists
EP2916836A4 (en) 2012-11-07 2016-08-03 Merck Sharp & Dohme AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE (SYK) INHIBITOR
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
BR112015017784A2 (pt) 2013-01-28 2017-07-11 Incozen Therapeutics Pvt Ltd método para tratar distúrbios autoimunes, respiratórios e inflamatórios por inalação de n-óxido de roflumilast
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
GB201305813D0 (en) 2013-03-28 2013-05-15 Vectura Ltd Compositions and methods
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
JP2016534976A (ja) 2013-05-23 2016-11-10 アズセラピーズ インコーポレイテッド クロモリンを送達する方法
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
EP3087980B1 (en) 2013-12-23 2018-12-05 Wen, Xiaoguang Double-layer tablet and preparation method thereof
EP4008726A1 (en) 2014-02-20 2022-06-08 Allergan, Inc. Complement component c5 antibodies
CA2977083A1 (en) * 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
EP3110845A1 (en) 2014-02-27 2017-01-04 Allergan, Inc. Complement factor bb antibodies
WO2015148415A2 (en) 2014-03-26 2015-10-01 Canget Biotekpharma, Llc Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
EP3126004A4 (en) 2014-04-02 2017-11-29 Rogne Bioscience Inc. Methods and compositions for treating inflammatory disorders
WO2015155544A1 (en) 2014-04-10 2015-10-15 Patrick Crowley Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
KR20150127315A (ko) 2014-05-07 2015-11-17 삼성중공업 주식회사 밸러스트수 처리 장치
KR102666667B1 (ko) * 2014-07-31 2024-05-17 벡추라 인코포레이티드 흡입용 건조 분말 제형
US20180056022A1 (en) 2015-03-21 2018-03-01 James Zhou Liu Hand-actuated dry powder inhaler and its use
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
CN106619549B (zh) * 2017-01-03 2019-12-06 江苏吴中医药集团有限公司苏州制药厂 一种替格瑞洛与阿司匹林复合片剂及其制备方法
EP3684338A4 (en) * 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE

Also Published As

Publication number Publication date
WO2019059953A2 (en) 2019-03-28
JP2022137070A (ja) 2022-09-21
JP7493449B2 (ja) 2024-05-31
KR102681843B1 (ko) 2024-07-05
AU2017432640B2 (en) 2023-11-30
KR20200090755A (ko) 2020-07-29
KR102507987B1 (ko) 2023-03-21
CA3076353A1 (en) 2019-03-28
AU2017432640A1 (en) 2020-03-19
KR20230040375A (ko) 2023-03-22
CN111315363A (zh) 2020-06-19
WO2019059953A3 (en) 2019-09-26
US20220016030A1 (en) 2022-01-20
CN111315363B (zh) 2022-10-11
JP2021502954A (ja) 2021-02-04
EP3684338A2 (en) 2020-07-29
MX2020002769A (es) 2020-07-20
US11077058B2 (en) 2021-08-03
EP3684338A4 (en) 2021-06-23
CN115919780A (zh) 2023-04-07
US10195147B1 (en) 2019-02-05
US20190336448A1 (en) 2019-11-07
JP7561162B2 (ja) 2024-10-03

Similar Documents

Publication Publication Date Title
MX2023006856A (es) Composiciones de polvo seco con estearato de magnesio.
MX2020011166A (es) Agentes crioprotectores para formulaciones en forma de particulas.
PH12017502326B1 (en) Orodispersible dosage unit containing an estetrol component
NZ723838A (en) Cannabinoid compositions and uses
WO2015160843A8 (en) Ion channel activators and methods of use
PH12017502325A1 (en) Orodispersible dosage unit containing an estetrol component
MX2015014337A (es) Composicion que comprende al menos dos polvos secos obtenidos por secado por pulverizacion para incrementar la estabilidad de la formulacion.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
IN2013MU01177A (es)
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2023003229A (es) Composicion para mejorar la absorcion de suplementos.
WO2020055357A3 (en) Inhalation compositions comprising phosphodiesterase-4 inhibitor
WO2019104062A8 (en) Polymorphs and uses thereof
WO2020013793A3 (en) Inhalation compositions comprising dopamine agonists
SA520420369B1 (ar) تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي
MX2022002681A (es) Composicion farmaceutica.
MX2019011701A (es) Composiciones de canabinoide y usos.
WO2019125166A3 (en) Hyaluronic acid formulations
PH12019500473A1 (en) Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles
MX2018013274A (es) Uso de alcoholes de azucar en composiciones de tibolona.
PH12018550075A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
MX2017002979A (es) Composiciones farmaceuticas de ofloxacino y ornidazol.